Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Abbott Laboratories, common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.27 0.27 0.29 0.30 0.30 0.31 0.30 0.30 0.30 0.30
Trade accounts payable 5.87 5.49 5.74 5.65 6.19 5.68 6.06 6.43 5.86 5.44 5.48 5.59 5.44 4.62 4.85 4.76 4.79 4.42 4.71 4.50
Salaries, wages and commissions 2.18 2.05 1.86 1.49 2.09 1.96 1.77 1.55 2.16 1.99 1.70 1.53 1.95 2.08 1.63 1.42 1.82 1.84 1.49 1.31
Other accrued liabilities 7.41 7.42 7.27 7.80 7.85 7.52 7.28 7.54 6.89 7.13 7.31 7.21 7.12 6.75 6.12 6.60 5.94 6.00 5.79 6.11
Dividends payable 1.30 1.23 1.21 1.20 1.19 1.13 1.11 1.11 1.11 1.08 1.09 1.10 1.10 0.93 0.93 0.95 0.94 0.83 0.83 0.84
Income taxes payable 0.67 0.44 0.37 0.45 0.46 0.54 0.48 0.46 0.41 0.50 0.33 0.38 0.50 0.17 0.24 0.25 0.33 0.10 0.12 0.41
Current portion of long-term debt 1.48 1.46 3.11 3.10 3.02 1.53 0.01 0.01 1.00 1.02 1.03 1.04 0.01 0.01 1.88 1.89 1.88 1.83 0.01 0.01
Current liabilities 18.90% 18.09% 19.56% 19.69% 20.81% 18.36% 16.70% 17.09% 17.43% 17.44% 17.22% 17.12% 16.41% 14.86% 15.93% 16.19% 16.00% 15.31% 13.24% 13.48%
Long-term debt, excluding current portion 18.57 20.08 19.85 19.81 19.51 21.01 22.58 23.09 23.00 23.64 23.95 24.03 25.54 26.58 26.44 25.16 24.54 25.74 27.74 27.87
Post-employment obligations, deferred income taxes and other long-term liabilities 9.49 9.54 9.59 10.05 10.11 11.34 11.24 11.68 11.66 11.98 12.39 12.43 12.56 12.81 12.85 13.09 13.35 12.24 12.41 12.61
Long-term liabilities 28.06% 29.62% 29.45% 29.86% 29.61% 32.35% 33.82% 34.77% 34.67% 35.63% 36.34% 36.46% 38.10% 39.38% 39.29% 38.25% 37.89% 37.98% 40.15% 40.48%
Total liabilities 46.97% 47.71% 49.01% 49.55% 50.42% 50.71% 50.52% 51.86% 52.09% 53.06% 53.56% 53.58% 54.51% 54.24% 55.22% 54.43% 53.89% 53.28% 53.39% 53.96%
Preferred shares, one dollar par value, none issued 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common shares, without par value, issued at stated capital amount 33.97 34.30 33.55 33.18 33.19 33.74 32.92 32.84 32.54 32.91 32.96 33.01 33.28 34.81 34.74 35.54 35.14 34.68 34.58 34.70
Common shares held in treasury, at cost -21.83 -21.76 -21.43 -20.74 -20.46 -19.99 -18.49 -18.55 -15.72 -14.90 -14.11 -13.53 -13.84 -14.30 -14.40 -14.84 -14.95 -14.05 -14.12 -14.32
Earnings employed in the business 51.29 51.21 49.56 48.61 47.36 48.23 46.48 44.99 41.93 41.16 39.65 39.39 38.08 38.04 37.32 38.62 38.07 37.12 36.60 36.40
Accumulated other comprehensive loss -10.71 -11.76 -11.00 -10.89 -10.82 -12.97 -11.73 -11.45 -11.14 -12.52 -12.37 -12.76 -12.33 -13.10 -13.20 -14.06 -12.47 -11.33 -10.76 -11.05
Total Abbott shareholders’ investment 52.73% 51.99% 50.68% 50.15% 49.28% 49.00% 49.18% 47.83% 47.61% 46.65% 46.13% 46.11% 45.19% 45.46% 44.46% 45.25% 45.79% 46.42% 46.31% 45.74%
Noncontrolling interests in subsidiaries 0.31 0.30 0.31 0.30 0.29 0.29 0.30 0.31 0.30 0.29 0.31 0.31 0.30 0.30 0.32 0.31 0.31 0.29 0.30 0.30
Total shareholders’ investment 53.03% 52.29% 50.99% 50.45% 49.58% 49.29% 49.48% 48.14% 47.91% 46.94% 46.44% 46.42% 45.49% 45.76% 44.78% 45.57% 46.11% 46.72% 46.61% 46.04%
Total liabilities and shareholders’ investment 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Abbott Laboratories current liabilities as a percentage of total liabilities and shareholders’ investment decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Abbott Laboratories long-term liabilities as a percentage of total liabilities and shareholders’ investment increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Abbott Laboratories total liabilities as a percentage of total liabilities and shareholders’ investment decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total Abbott shareholders’ investment Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Abbott Laboratories total Abbott shareholders’ investment as a percentage of total liabilities and shareholders’ investment increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.